Sanofi

How Sanofi’s Biopharma Partnerships Are Advancing Digital and AI Innovation

Published on: November 17, 2026

Share

A Sanofi colleague and a partner discuss a collaboration beside a staircase in a bright office.
Sanofi and a partner collaborating on digital partnership

Sanofi’s ability to lead in biopharma innovation has always been tied to our commitment to building strategic partnerships ౼ a foundation that serves us well in this new era of healthcare. Today, the scale of AI-driven innovation has made partnerships a strategic necessity. After all, no single company has all the data, all the models, and all the biological expertise to build what comes next. These partnerships strengthen capabilities across the ecosystem, benefiting every partner along the way, and ultimately driving greater impact for patients. 

Our Approach to Digital Partnership in Biopharma

As we navigate this shifting landscape, we focus on partnerships that create real impact ౼ bringing us ever closer to our ultimate goal: significantly reducing the time between scientific discovery and treatment delivery for patients. This mission shapes every decision we make, including how we develop the AI capabilities our teams need most. It leads to a single strategic question at the heart of our Digital partnership efforts: how can we develop differentiated capabilities that accelerate our ambition to deliver AI at scale, and what is the fastest path to getting there? The structure of every partnership flows from that answer.  

Partnerships Designed for Long-Term Impact  

While Sanofi remains focused on developing proprietary Digital and AI capabilities, our strategic advantage is built on a two-pronged approach that combines in-house innovation with partnerships across a trusted ecosystem. Through diverse levels of partnerships spanning strategic investments, licensing, technology collaborations and co-development, we are building a portfolio of best-in-class innovation and complementary Digital and AI capabilities. 

What distinguishes our approach is not only the partnerships we pursue, but how we build and grow them. Every collaboration begins with a clear objective ౼ identifying the capabilities needed to accelerate scientific discovery and patient benefits and selecting the partnership model best suited to deliver. Our most strategic partnerships go beyond technology adoption, enabling us to co-build capabilities that strengthen our long-term competitive advantage.  

This approach comes to life through the following three partnerships that advance our digital strategy in distinct ways. Two focus on strengthening AI capabilities, while the third supports digital solutions for patients. Together, from Digital to AI focused, they illustrate how we tailor each collaboration to the capabilities needed and the value we aim to deliver.   

Circular diagram of Sanofi's digital partnerships in biopharma, leading to digital and AI capabilities at the center, and linking to three partnership types: Discover Better, Operate Smarter and Scale Responsibly.

Sanofi's vision and approach for developing digital and AI capabilities in biopharma through digital partnerships.

Discover Better: Turns Data into Scientific Intelligence with Owkin

AI-enabled scientific insights and target discovery are shortening the path from biology to breakthrough.   

The Partnership

In 2021, Sanofi took a deliberate and early bet that the AI capabilities most valuable to drug discovery would come from strategic collaborations rather than developing them alone. With that in mind, we partnered with Owkin, combining its AI capabilities and multimodal patient data with Sanofi’s scientific expertise and robust datasets.  

Starting with target identification in oncology, our collaboration expanded into immunology asset prioritization, with Owkin delivering datasets, models and biomarkers to support Sanofi’s scientific and portfolio decision-making. As Sanofi’s scientific priorities and portfolio goals evolve, so does the focus of our work.  

Today, the partnership is expanding, as AI becomes part of daily research and decision-making. Sanofi is now partnering with Owkin on a multi-year collaboration to build novel AI-driven biopharma agents, leveraging K Pro, Owkin's AI Scientist, that will deepen the integration of AI into research workflows and corporate strategy.  

Operate Smarter: Brings AI Closer to the Point of Decision with CytoReason

Developing computation disease models and predictive simulations that transform assumption test, insights generation, and R&D decision velocity.

The Partnership

When Sanofi first partnered with CytoReason, a company that combines AI-powered computational disease models with multi-modal data, we started with research projects focused on in asthma and inflammatory bowel disease. Today, that collaboration has evolved into a broader disease intelligence capability, bringing insights closer to the decisions that inform our R&D portfolio. Led by the Target, Disease & Systems Biology function, the partnership supports Sanofi’s research strategy. 

By combining molecular, clinical and real-world data with computational modeling, the partnership helps researchers deepen their understanding of disease biology, prioritize targets and assess potential target combinations. To date, the collaboration has supported five immunology programs and deployed six additional disease models, generating insights to support target prioritization and patient stratification in inflammatory bowel disease and asthma.  

The new chapter of the partnership focuses on making these capabilities more accessible within scientific workflows. CytoReason’s new research agent is now live, creating another way for our R&D teams to explore disease insights. As we look ahead, our focus is on expanding platform use, leveraging proprietary datasets, extending coverage to additional data modalities and demonstrating how these insights inform scientific decisions. Achievements to date and insights generated indicate that a scalable AI-driven intelligence capability can reduce analysis times from weeks to hours. 

Scale Responsibly: Turns Digital Health Innovation into Patient Impact with BrightInsight

Building the digital infrastructure and reusable capabilities that help patient support solutions to scale.  

The Partnership

Our partnership with BrightInsight provides the digital infrastructure that enables Sanofi to scale connected patient support solutions across products, geographies, regulatory regimes and therapeutic areas. This partnership has established reusable enterprise capabilities that transform individual digital solutions into a global platform for patient engagement. 

The co-developed platform is designed to accommodate different patient needs from fully autonomous digital experience to hybrid care models with human support. This enables Sanofi to deploy, adapt and continuously improve our digital health solutions at scale   

Today, the platform is being leveraged by different programs active across the US, Japan, the Gulf, Canada and Spain. For the program in the US, it has enrolled approximately 65,000 patients. For a separate program in Spain, it has already guided over 200 patients through self-management, with Germany set to launch its digital experience in 2026. Further expansion is planned which signals the platform’s growing role as reusable global infrastructure for patient support activities, extending the value of a single shared foundation across new markets and patient populations. 

Building the Capabilities of Tomorrow Through Digital and AI Partnerships

Together, these three areas form a coherent external growth strategy rather than a collection of individual initiatives. Each partnership contributes to a broader portfolio of capabilities that reinforces and expands our long-term AI ambitions. Insights generated through real-world deployment continuously strengthen our capabilities across discovery, operations, patient engagement and broader areas across our value chain. 

Partnerships Built with Trust

Speed alone is not a strategy. All of Sanofi's external AI collaborations are guided by RAISE, Sanofi’s responsible AI for everyone framework, which governs that innovation advances with the rigor and trust required in healthcare. RAISE also provides the design principle embedded from the outset of every project. It gives our partners confidence that the solutions we develop together can scale while ensuring that progress remains ethical, compliant, and sustainable.  

Throughout the partnership lifecycle, dedicated partnership leaders help maintain alignment across internal teams and external collaborators, helping each collaboration to evolve alongside changing scientific priorities and business needs.  

Co-Building the Future of Healthcare

These partnerships share a common principle: Sanofi is an active co-builder. We bring the data, the clinical context, and scientific challenges that external partners cannot access on their own, creating capabilities that amplify innovation and impact - AI agents are moving from concepts into scientific workflows. Disease models are evolving from individual analyses into portfolio-wide decision support. Connected patient platforms are scaling from standalone products into reusable infrastructure. The partnerships we are building today are not just accelerating what Sanofi can achieve now — they are reinventing the capabilities, platforms, and ways of working that will define our future. 

While co-building is one type of partnership we’re developing, it’s part of a broader ecosystem of collaborations, each with the same ambition: to reduce the time to treatment for patients worldwide. We’ll continue to share how broader partnerships help us turn our ambition into reality.

Explore More

Artificial Intelligence and Digital Transformation in Biopharma

Artificial Intelligence in R&D

How Digital & AI in Patient Care Transforms the Daily Care Journey